AVIR (Atea Pharmaceuticals) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.49
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Tariff Resilience Score?

Atea Pharmaceuticals AVIR +3.34% 24 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,376 Biotechnology companies, Atea Pharmaceuticals ranks better than 90.41% on this metric.

Atea Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Atea Pharmaceuticals has Pharmaceuticals face moderate tariff risks. Global supply chain but essential nature of products often leads to exemptions. R&D focus limits immediate tariff impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Atea Pharmaceuticals might have Highly Resilient.

Atea Pharmaceuticals  (NAS:AVIR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Atea Pharmaceuticals Tariff Resilience Score Related Terms

AVIR vs IMRX, PROK, NWBO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Atea Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Tariff Resilience Score falls into.


AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Atea Pharmaceuticals (AVIR) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Atea Pharmaceuticals ranks #132 out of 1376 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Atea Pharmaceuticals' Tariff Resilience Score too high?
Atea Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Atea Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Atea Pharmaceuticals ranks #132 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Tariff Resilience Score compare to IMRX and PROK?
According to the Biotechnology industry distribution chart, Atea Pharmaceuticals ranks #132 out of 1376 companies for Tariff Resilience Score. This places Atea Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Atea Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atea Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atea Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price